Business
Biotech Companies Invest in New Obesity Treatments
Eli Lilly and Novo Nordisk are developing new amylin drugs to treat obesity and diabetes, following the success of GLP-1 medications.
Coverage timeline — 1 article
CNBC
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
2026-10-02 15:20 UTC